Print Page | Sign In | Join
News & Press: Other

Lipid drug delivery: Sancilio Pharmaceuticals files for an $86 million IPO

Monday, August 31, 2015   (0 Comments)
Share |

August 31

SOURCE: Renaissance Capital

 

Lipid drug delivery: Sancilio Pharmaceuticals files for an $86 million IPO

 

Sancilio Pharmaceuticals Company, which markets, licenses and develops products based on its lipid drug delivery technology, filed on Monday with the SEC to raise up to $86 million in an initial public offering.

The Riviera Beach, FL-based company, which was founded in 2006 and booked $22 million in revenue for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol SPCI. Sancilio Pharmaceuticals initially filed confidentially on May 14, 2015. UBS Investment Bank, Piper Jaffray, JMP Securities and FBR Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.

 

The article Lipid drug delivery: Sancilio Pharmaceuticals files for an $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.


About BioFlorida

BioFlorida represents nearly 6,000 establishments and research organizations in the biopharmaceutical, medical technology and bioagriculture sectors that collectively employ nearly 83,000 Floridians.

 

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

Email us for a regional Chapter sponsorship.

Connect